With the continuous evolution of cancer treatments worldwide, precision oncology is experiencing a growing demand. In response, HanchorBio Inc. (TWSE: 7827), a global, clinical-stage biotechnology company dedicated to creating next-generation immunotherapies for cancer and immune-mediated conditions, has revealed a new collaboration. The company is teaming up with a National Taiwan University (NTU) research group led by Professor Sung-Liang Yu from the Department of Clinical Laboratory Sciences and Medical Biotechnology, which plays a vital role in the Taiwan Cancer Moonshot Project (TCMP). This cross-disciplinary alliance was officially established via a memorandum of understanding (MOU) signed on August 7, setting the stage for long-term cooperation aimed at accelerating precision immunotherapy and the development of novel cancer therapeutics. Taiwan Cancer Moonshot Project Drives Asian Tumor Multi-Omics Research Launched in 2016 through a memorandum of understanding with the U.S. National Cancer Institute (NCI), TCMP is a precision-oncology research initiative that joined the US-led Cancer …

HanchorBio Partners with Taiwan Cancer Moonshot Project to Advance Next-Generation Precision Immuno-Oncology Read More »

After two decades of rapid scientific breakthroughs—from immunotherapies and targeted medicines to antibody-drug conjugates (ADCs)—oncology is entering a new phase. The challenge is no longer simply developing innovative cancer treatments, but ensuring healthcare systems can deliver them sustainably and equitably through timely diagnostics, reimbursement, and patient access. “Cancer isn’t a death sentence anymore—or it doesn’t have to be,” said Tina Graves, Vice President and General Manager of GSK Taiwan. “If we focus on therapies that improve long-term outcomes and quality of life, our goal at GSK is to make cancer a curable disease.” Echoing that vision, Graves and Tony Pao, Country Medical Director at GSK Taiwan, emphasized that scientific innovation has little value without access. “We’re in the industry of patient care,” Graves said. “Patients are 100% at the center of everything we do.” Precision Medicine Is Redefining What “Best-in-Class” Means Historically, oncology success was measured through endpoints such as tumor …

Oncology’s Next Challenge Isn’t Innovation—It’s Delivery Read More »

At BIO Asia–Taiwan 2026, EirGenix (TWSE: 6589) showcased its end-to-end biologics development and manufacturing capabilities through its exhibition booth and Mini Talks series, highlighting key aspects across the biologics value chain — from plasmid DNA (pDNA) manufacturing and bioanalytical technologies to expression system selection and antibody-drug conjugate (ADC) development strategies. Developing a successful biologic requires far more than discovering a promising molecule. The company demonstrated how its integrated platforms, technical expertise, and extensive biologics development experience can help partners mitigate risks, improve development efficiency, and accelerate the path toward commercialization. In an exclusive interview with GeneOnline, Lee-Cheng Liu, Founder, Chairman of EirGenix, emphasized that as biologics continue to advance rapidly, success depends not only on innovative therapeutic mechanisms but also on the underlying capabilities that enable products to progress through clinical development and achieve commercial success. “Even as emerging modalities such as ADCs and bispecific antibodies (BsAbs) attract increasing investment …

EirGenix Showcases End-to-End Biologics Platform at BIO Asia–Taiwan, Highlighting CDMO Growth Read More »